中药注射液联合化疗药物治疗卵巢癌的网状Meta分析
|
摘要
目的对中药注射液联合化疗药物治疗卵巢癌的效果和安全性进行系统评价。方法检索PubMed数据库、万方、维普、中国知网、中国生物医学文献数据库,并人工检索相关会议、专业杂志等,收集中药注射液联合化疗药物治疗卵巢癌的随机对照试验(RCT),检索时间为建库至2018年6月。以ADDIS 1.16.8软件进行网状Meta分析。结果最终纳入35个RCTs,包含2 546例患者。分析结果显示:(1)鸦胆子、艾迪、消癌平、复方苦参、康艾、参芪扶正6种注射液联合化疗能提高总有效率,且鸦胆子效果显著优于复方苦参、康艾、参芪扶正。华蟾素、参麦、消癌平、艾迪、复方苦参、康艾、参芪扶正7种注射液联合化疗能提高生活质量;艾迪、康艾、参麦、参芪扶正4种注射液联合化疗能缓解胃肠不良反应;艾迪、复方苦参、康艾、参麦、参芪扶正5种注射液联合化疗能减轻骨髓抑制;复方苦参联合化疗能保护肝肾功能,以上结果差异均有统计学意义(P<0.05)。(2)最佳概率排序,(1)提高总有效率:鸦胆子>消癌平>参芪扶正>艾迪>康艾>复方苦参;(2)改善患者生活质量:华蟾素>参麦>消癌平>艾迪>复方苦参>康艾>参芪扶正;(3)缓解胃肠道反应:参芪扶正>参麦>康艾>艾迪。(4)减轻骨髓抑制:复方苦参>参芪扶正>康艾>参麦>艾迪。结论提高总有效率以鸦胆子效果最佳;改善生活质量首推华蟾素;缓解胃肠反应优先选择参芪扶正;而减轻骨髓抑制、保护肝肾功能复方苦参效果最好。
Objective To evaluate the attenuated synergistic mechanism of traditional Chinese medicine injectioncombined with chemotherapy drugs in treating ovarian cancer. Methods We searched the PubMed database,Wanfang,VIP,CNKI,CBMdisc databases and manually retrieved journals and conferences,collected randomizedcontrolled trial(RCT) of Chinese medicine injection combined with chemotherapy drugs in treating ovarian cancer,up to June 2018 since database establishment. The network meta-analysis was conducted using ADDIS 1.16.8software. Results Thirty-five RCTs with 2 546 patients were included in the study. The results show that:(1) Sixkinds of injections(Brucea javanica oil, Aidi, Xiaoaiping, Compound Kushen, Kang' ai, Shenqi Fuzheng)combined with chemotherapy can improve the total efficiency and Brucea javanica oil is better than CompoundKushen,Kang'ai,Shenqi Fuzheng. Seven kinds of injections including Huachansu,Shenmai,Xiaoaiping,Aidi,Compound Kushen,Kang'ai,Shenqi Fuzheng combined with chemotherapy can improve the quality of life. Fourkinds of injections including Aidi,Kang'ai,Shenmai,Shenqi Fuzheng combined with chemotherapy can alleviategastrointestinal reaction. Five kinds of injections including Aidi,Compound Kushen,Kang'ai,Shenmai,ShenqiFuzheng combined with chemotherapy can reduce bone marrow suppression. Compound Kushen combined withchemotherapy can protect the liver and kidney function. The differences were statistically significant.(2) Theprobability sorting are as follows:(1) The total efficiency: Brucea javanica oil>Xiaoaiping>Shenqi Fuzheng>Aidi>Kang'ai>Compound Kushen.(2) The quality of life: Huachansu>Shenmai>Xiaoaiping>Aidi>CompoundKushen>Kang'ai>Shenqi Fuzheng.(3) Alleviating gastrointestinal reaction:Shenqi Fuzheng>Shenmai>Kang'ai>Aidi.(4)Reducing bone marrow suppression:Compound Kushen>Shenmai>Kang'ai>Shenmai>Aidi. Conclusion Brucea javanica oil is the best in improving the total efficiency;Huachansu is the best in improving the quality oflife;Shenqi Fuzheng is priority selection for alleviating gastrointestinal reaction;and Compound Kushen is the bestin reducing bone marrow suppression,protecting the liver and kidney function.
Objective To evaluate the attenuated synergistic mechanism of traditional Chinese medicine injectioncombined with chemotherapy drugs in treating ovarian cancer. Methods We searched the PubMed database,Wanfang,VIP,CNKI,CBMdisc databases and manually retrieved journals and conferences,collected randomizedcontrolled trial(RCT) of Chinese medicine injection combined with chemotherapy drugs in treating ovarian cancer,up to June 2018 since database establishment. The network meta-analysis was conducted using ADDIS 1.16.8software. Results Thirty-five RCTs with 2 546 patients were included in the study. The results show that:(1) Sixkinds of injections(Brucea javanica oil, Aidi, Xiaoaiping, Compound Kushen, Kang' ai, Shenqi Fuzheng)combined with chemotherapy can improve the total efficiency and Brucea javanica oil is better than CompoundKushen,Kang'ai,Shenqi Fuzheng. Seven kinds of injections including Huachansu,Shenmai,Xiaoaiping,Aidi,Compound Kushen,Kang'ai,Shenqi Fuzheng combined with chemotherapy can improve the quality of life. Fourkinds of injections including Aidi,Kang'ai,Shenmai,Shenqi Fuzheng combined with chemotherapy can alleviategastrointestinal reaction. Five kinds of injections including Aidi,Compound Kushen,Kang'ai,Shenmai,ShenqiFuzheng combined with chemotherapy can reduce bone marrow suppression. Compound Kushen combined withchemotherapy can protect the liver and kidney function. The differences were statistically significant.(2) Theprobability sorting are as follows:(1) The total efficiency: Brucea javanica oil>Xiaoaiping>Shenqi Fuzheng>Aidi>Kang'ai>Compound Kushen.(2) The quality of life: Huachansu>Shenmai>Xiaoaiping>Aidi>CompoundKushen>Kang'ai>Shenqi Fuzheng.(3) Alleviating gastrointestinal reaction:Shenqi Fuzheng>Shenmai>Kang'ai>Aidi.(4)Reducing bone marrow suppression:Compound Kushen>Shenmai>Kang'ai>Shenmai>Aidi. Conclusion Brucea javanica oil is the best in improving the total efficiency;Huachansu is the best in improving the quality oflife;Shenqi Fuzheng is priority selection for alleviating gastrointestinal reaction;and Compound Kushen is the bestin reducing bone marrow suppression,protecting the liver and kidney function.
引文
[1]曹丽娟,刘文博.miR-497和miR-34a在铂敏感和铂耐药卵巢上皮癌患者中的表达差异及机制研究[J].中国药房,2017,28(17):2308-2313.
[2]齐聪,张勤华,李久现,等.增免抑瘤方联合顺铂对铂类耐药卵巢癌抑瘤率影响的实验研究[J].中国中西医结合杂志,2012,32(6):817-821.
[3]PICCART M J,BERTELSEN K,JAMES K,et al.Randomized intergroup trial of cisplatin-paclitaxel versus cisplatincyclo-phosphamide in women with advanced epithelial ovarian cancer:three-year results[J].J Natl Cancer Inst,2000,92(9):699-708.
[4]VAUGHAN S,COWARD J I,BAST R C,et al.Rethinking ovarian cancer:recommendations for improving outcomes[J].Nat Rev Cancer,2011,11(10):719-725.
[5]杨红,钱麟,周华,等.中药活性成分逆转卵巢癌化疗耐药机制的研究进展[J].中国中西医结合杂志,2013,33(6):861-864.
[6]李悦,张艳,郭滢,等.卵巢癌的中医药研究应用进展[J].辽宁中医杂志,2016,43(1):194-196.
[7]宋建武,李翠兵,宋欣颖,等.中药注射剂辅助PD方案治疗晚期卵巢癌的临床效果与经济学评价[J].现代肿瘤医学,2013,21(12):2796-2798.
[8]葛龙,毛蕾,田金徽,等.食管癌放疗过程中如何选择中药注射剂的网状Meta分析[J].中国中药杂志,2015,18(40),3674-3681.
[9]刘应生,白钰,吕书勤,等.鸦胆子油乳联合TACE治疗中晚期原发性肝癌疗效和安全性Meta分析[J].中国中西医结合杂志,2017,37(9):1063-1068.
[10]MOR V,LALIBERTE L,MORRIS J N,et al.The Karnofsky Performance Status Scale:An examination of its reliability and validity in a research setting[J].Cancer,1984,53(9):2002-2007.
[11]HIGGINS J P,ALTMAN D G,GOTZSCHE P C,et al.The Cochrane collaboration's tool for assessing risk of bias in randomised trials[J].BMJ,2011,343:d5928.
[12]张超,鄢金柱,孙凤,等.网状Meta分析一致性的鉴别与处理方法[J].中国循证医学杂志,2014,14(7):884-888.
[13]刘青,杨颖,刘开江,等.艾迪注射液辅助治疗卵巢癌性腹水的临床疗效观察[J].新疆医学,2008,38(3):34-35.
[14]马媛.艾迪注射液联合PAC方案化疗治疗晚期卵巢上皮癌的临床研究[J].中国医药导刊,2009,11(4):603-606.
[15]钟荣钟,肖文辉,林洁,等.艾迪注射液联合TC方案治疗晚期上皮性卵巢癌的临床疗效分析[J].肿瘤药学,2014,4(5):366-369.
[16]付建红,高湛,翟旭华.艾迪注射液联合化疗用于老年女性卵巢癌术后辅助治疗的疗效评价[J].中国老年学杂志,2013,33(16):3973-3975.
[17]黎壮伟.艾迪注射液联合化疗治疗晚期卵巢癌30例[J].实用中医内科杂志,2012,26(6):5-8.
[18]刘通,池桂玲.艾迪注射液联合化疗治疗晚期卵巢癌的临床观察[J].中外医疗,2008,27(10):328-329.
[19]曹芹雪.艾迪注射液联合化疗治疗晚期卵巢癌的临床研究[J].中药药理与临床,2016,32(1):184-186.
[20]赖晓红.参附注射液在PVB方案治疗晚期卵巢癌中应用的临床观察[J].临床和实验医学杂志,2008,7(11):87-88.
[21]梁丹,杨美春,林忠,等.莪术油注射液配合常规了化疗干预卵巢癌的疗效观察[J].中医临床研究,2014,6(4):7-8.
[22]何际平.华蟾素注射液联合化疗治疗晚期卵巢癌疗效观察[J].南华大学学报:医学版,2010,38(3):420-421.
[23]郝颂华,杨玲竹,王欣.参麦注射液联合TP方案治疗晚期卵巢癌疗效观察[J].肿瘤基础与临床,2010,23(4):315-316.
[24]徐小琴,曾韶英,王茂淮,等.参麦注射液联合西药治疗中晚期卵巢癌24例[J].中国中医药现代远程教育,2015,13(21):84-85.
[25]赵能彩.参麦注射液联合紫杉醇和卡铂治疗中晚期卵巢癌24例疗效观察[J].新中医,2014,46(7):138-140.
[26]王翠英,宋春燕.参麦注射液治疗卵巢癌临床研究[J].中医学报,2013,28(4):471-472.
[27]狄晓鸿,吕瑞.TP化疗方案联合参芪扶正注射液治疗晚期卵巢癌的临床观察[J].西部中医药,2015,28(8):1-3.
[28]于聪,冯小丽.参芪扶正注射液联合TP方案治疗卵巢癌的临床分析[J].中国当代医药,2017,24(8):64-65.
[29]王丽霞,王丽峰.参芪扶正注射液联合紫杉醇和顺铂方案治疗晚期卵巢癌的临床疗效[J].中国肿瘤临床与康复,2015,22(12):1459-1461.
[30]王立成.化疗联合康艾注射液治疗晚期卵巢癌的效果观察[J].中国卫生标准管理,2015,6(3):84-86.
[31]黄晶,张才友,余瑛,等.康艾注射液联合化疗在卵巢癌术后辅助治疗中的疗效评价[J].赣南医学院学报,2014,34(4):563-567.
[32]李海金,董良,李英,等.康艾注射液联合化疗治疗晚期卵巢癌48例近期疗效观察[J].浙江中西医结合杂志,2017,27(8):682-685.
[33]王晓彬,刘佳,席红,等.康艾注射液联合化疗治疗晚期卵巢癌120例[J].辽宁中医杂志,2014,41(1):81-83.
[34]范小琴.康艾注射液联合化疗治疗晚期卵巢癌临床研究[J].基层医学论坛,2015,19(8):1011-1012.
[35]李娟.复方苦参注射液辅助TP方案治疗晚期卵巢肿瘤患者临床疗效及对其免疫功能的影响[J].亚太传统医药,2014,10(18):105-106.
[36]张同兴,赵家彬,刘荣花,等.复方苦参注射液及顺铂联合微波热疗治疗卵巢癌腹水的临床观察[J].现代肿瘤医学,2016,24(9):1443-1445.
[37]罗芳.复方苦参注射液联合TP方案治疗晚期卵巢癌的疗效观察[J].现代中西医结合杂志,2012,21(32):3584-3585.
[38]闫秀云.复方苦参注射液联合多西他赛+卡铂治疗晚期卵巢癌87例临床观察[J].中国医院用药评价与分析,2011,11(9):835-836.
[39]王子熹,姜永华.复方苦参注射液联合化疗在晚期卵巢癌中的综合疗效研究[J].中国医师进修杂志,2012,35(12):21-23.
[40]林春丽.复方苦参注射液联合化疗治疗晚期卵巢癌的临床效果研究[J].中医临床研究,2011,3(5):28-29.
[41]梁倩影,彭大为.复方苦参注射液联合紫杉醇与顺铂治疗晚期卵巢癌的临床疗效[J].实用肿瘤杂志,2015,30(5):465-468.
[42]王媛.复方苦参注射液配合腹腔灌注化疗治疗卵巢癌腹腔积液临床研究[J].中国中医药信息杂志,2015,22(5):25-28.
[43]张涛,徐海亭,惠华,等.洛铂与复方苦参注射液联合腹腔灌注治疗卵巢癌并发恶性腹水的疗效及其对肿瘤坏死因子的影响[J].中国基层医药,2017,24(15):2281-2284.
[44]郝玉珍,吴英,冀秋凤,等.消癌平联合PC方案治疗晚期卵巢癌的临床研究[J].西北国防医学杂志,2016,37(10):679-681.
[45]李凤霞,宋爱英,唐寅,等.消癌平注射液直肠给药联合常规化疗治疗上皮性卵巢癌的临床观察[J].中国药房,2015,26(20):2815-2817.
[46]汤巍巍,于明新,尉阳,等.新辅助化疗联合鸦胆子油注射剂治疗晚期卵巢癌的疗效观察[J].中医药导报,2014,20(4):21-22.
[47]徐卫东.鸦胆子油乳联合化疗治疗复发性卵巢癌37例[J].浙江中西医结合杂志,2008,18(6):382-383.
[48]王淳,董秀,王梅,等.消癌平注射液增敏奥沙利铂抑制卵巢癌Caov-3细胞的增殖[J].肿瘤防治研究,2012,39(7):780-783.
[49]白晓菊.中药注射剂抗肿瘤品种分析[J].中药药理与临床,2009,25(3):72-73.
[50]赵楠,李玉花,吴效科.鸦胆子油乳及联合顺铂对卵巢癌SKOV3裸鼠移植瘤生长抑制的影响[J].中国中西医结合杂志,2015,35(1):57-62.
[51]李戈,赵晨,思金华,等.19种中药注射剂联合TACE治疗中晚期肝细胞癌的网状Meta分析[J].兰州大学学报(医学版),2016,42(3):58-63,72.
[52]张涛,凌解春,秦裔丽.参麦注射液临床新用[J].时珍国医国药,2005,16(3):245.
[53]王宁军,芦殿荣,杨柳,等.华蟾素缓解癌性疼痛作用机制的研究进展[J].世界中西医结合杂志,2016,11(4):590-592.
[54]刘云霞,匡唐洪,蒋沈君.华蟾素注射液改善晚期癌症患者生活质量的临床观察[J].中国中医药科技,2005,12(1):45-46.
[55]贾小晴,孙萍,等.华蟾素抗肿瘤成分及作用机制研究进展[J].辽宁中医药大学学报,2017,19(3):215-217.
[56]赵洁敏,吴爱珍,石亮荣,等.参芪扶正注射液联合多西紫杉醇加氟脲嘧啶/亚叶酸钙治疗晚期胃癌的临床观察[J].中国中西医结合杂志,2007,27(8):736-738.
[57]耿维凤,陈敏.参芪扶正注射液临床初步观察[J].中国医院药学杂志,2003,23(9):554-555.
[58]李经才.药理学总论[M].北京:人民卫生出版社,2005:536.
[59]苏瑞,李玲,徐宏彬,等.复方苦参注射液对胃肠道恶性肿瘤辅助治疗的临床观察[J].中国医院药学杂志,2015,35(4):322-325.
[60]宣丽君.复方苦参注射液对化疗减毒作用的临床观察[J].实用中医内科杂志,2005,19(3):275.
[2]齐聪,张勤华,李久现,等.增免抑瘤方联合顺铂对铂类耐药卵巢癌抑瘤率影响的实验研究[J].中国中西医结合杂志,2012,32(6):817-821.
[3]PICCART M J,BERTELSEN K,JAMES K,et al.Randomized intergroup trial of cisplatin-paclitaxel versus cisplatincyclo-phosphamide in women with advanced epithelial ovarian cancer:three-year results[J].J Natl Cancer Inst,2000,92(9):699-708.
[4]VAUGHAN S,COWARD J I,BAST R C,et al.Rethinking ovarian cancer:recommendations for improving outcomes[J].Nat Rev Cancer,2011,11(10):719-725.
[5]杨红,钱麟,周华,等.中药活性成分逆转卵巢癌化疗耐药机制的研究进展[J].中国中西医结合杂志,2013,33(6):861-864.
[6]李悦,张艳,郭滢,等.卵巢癌的中医药研究应用进展[J].辽宁中医杂志,2016,43(1):194-196.
[7]宋建武,李翠兵,宋欣颖,等.中药注射剂辅助PD方案治疗晚期卵巢癌的临床效果与经济学评价[J].现代肿瘤医学,2013,21(12):2796-2798.
[8]葛龙,毛蕾,田金徽,等.食管癌放疗过程中如何选择中药注射剂的网状Meta分析[J].中国中药杂志,2015,18(40),3674-3681.
[9]刘应生,白钰,吕书勤,等.鸦胆子油乳联合TACE治疗中晚期原发性肝癌疗效和安全性Meta分析[J].中国中西医结合杂志,2017,37(9):1063-1068.
[10]MOR V,LALIBERTE L,MORRIS J N,et al.The Karnofsky Performance Status Scale:An examination of its reliability and validity in a research setting[J].Cancer,1984,53(9):2002-2007.
[11]HIGGINS J P,ALTMAN D G,GOTZSCHE P C,et al.The Cochrane collaboration's tool for assessing risk of bias in randomised trials[J].BMJ,2011,343:d5928.
[12]张超,鄢金柱,孙凤,等.网状Meta分析一致性的鉴别与处理方法[J].中国循证医学杂志,2014,14(7):884-888.
[13]刘青,杨颖,刘开江,等.艾迪注射液辅助治疗卵巢癌性腹水的临床疗效观察[J].新疆医学,2008,38(3):34-35.
[14]马媛.艾迪注射液联合PAC方案化疗治疗晚期卵巢上皮癌的临床研究[J].中国医药导刊,2009,11(4):603-606.
[15]钟荣钟,肖文辉,林洁,等.艾迪注射液联合TC方案治疗晚期上皮性卵巢癌的临床疗效分析[J].肿瘤药学,2014,4(5):366-369.
[16]付建红,高湛,翟旭华.艾迪注射液联合化疗用于老年女性卵巢癌术后辅助治疗的疗效评价[J].中国老年学杂志,2013,33(16):3973-3975.
[17]黎壮伟.艾迪注射液联合化疗治疗晚期卵巢癌30例[J].实用中医内科杂志,2012,26(6):5-8.
[18]刘通,池桂玲.艾迪注射液联合化疗治疗晚期卵巢癌的临床观察[J].中外医疗,2008,27(10):328-329.
[19]曹芹雪.艾迪注射液联合化疗治疗晚期卵巢癌的临床研究[J].中药药理与临床,2016,32(1):184-186.
[20]赖晓红.参附注射液在PVB方案治疗晚期卵巢癌中应用的临床观察[J].临床和实验医学杂志,2008,7(11):87-88.
[21]梁丹,杨美春,林忠,等.莪术油注射液配合常规了化疗干预卵巢癌的疗效观察[J].中医临床研究,2014,6(4):7-8.
[22]何际平.华蟾素注射液联合化疗治疗晚期卵巢癌疗效观察[J].南华大学学报:医学版,2010,38(3):420-421.
[23]郝颂华,杨玲竹,王欣.参麦注射液联合TP方案治疗晚期卵巢癌疗效观察[J].肿瘤基础与临床,2010,23(4):315-316.
[24]徐小琴,曾韶英,王茂淮,等.参麦注射液联合西药治疗中晚期卵巢癌24例[J].中国中医药现代远程教育,2015,13(21):84-85.
[25]赵能彩.参麦注射液联合紫杉醇和卡铂治疗中晚期卵巢癌24例疗效观察[J].新中医,2014,46(7):138-140.
[26]王翠英,宋春燕.参麦注射液治疗卵巢癌临床研究[J].中医学报,2013,28(4):471-472.
[27]狄晓鸿,吕瑞.TP化疗方案联合参芪扶正注射液治疗晚期卵巢癌的临床观察[J].西部中医药,2015,28(8):1-3.
[28]于聪,冯小丽.参芪扶正注射液联合TP方案治疗卵巢癌的临床分析[J].中国当代医药,2017,24(8):64-65.
[29]王丽霞,王丽峰.参芪扶正注射液联合紫杉醇和顺铂方案治疗晚期卵巢癌的临床疗效[J].中国肿瘤临床与康复,2015,22(12):1459-1461.
[30]王立成.化疗联合康艾注射液治疗晚期卵巢癌的效果观察[J].中国卫生标准管理,2015,6(3):84-86.
[31]黄晶,张才友,余瑛,等.康艾注射液联合化疗在卵巢癌术后辅助治疗中的疗效评价[J].赣南医学院学报,2014,34(4):563-567.
[32]李海金,董良,李英,等.康艾注射液联合化疗治疗晚期卵巢癌48例近期疗效观察[J].浙江中西医结合杂志,2017,27(8):682-685.
[33]王晓彬,刘佳,席红,等.康艾注射液联合化疗治疗晚期卵巢癌120例[J].辽宁中医杂志,2014,41(1):81-83.
[34]范小琴.康艾注射液联合化疗治疗晚期卵巢癌临床研究[J].基层医学论坛,2015,19(8):1011-1012.
[35]李娟.复方苦参注射液辅助TP方案治疗晚期卵巢肿瘤患者临床疗效及对其免疫功能的影响[J].亚太传统医药,2014,10(18):105-106.
[36]张同兴,赵家彬,刘荣花,等.复方苦参注射液及顺铂联合微波热疗治疗卵巢癌腹水的临床观察[J].现代肿瘤医学,2016,24(9):1443-1445.
[37]罗芳.复方苦参注射液联合TP方案治疗晚期卵巢癌的疗效观察[J].现代中西医结合杂志,2012,21(32):3584-3585.
[38]闫秀云.复方苦参注射液联合多西他赛+卡铂治疗晚期卵巢癌87例临床观察[J].中国医院用药评价与分析,2011,11(9):835-836.
[39]王子熹,姜永华.复方苦参注射液联合化疗在晚期卵巢癌中的综合疗效研究[J].中国医师进修杂志,2012,35(12):21-23.
[40]林春丽.复方苦参注射液联合化疗治疗晚期卵巢癌的临床效果研究[J].中医临床研究,2011,3(5):28-29.
[41]梁倩影,彭大为.复方苦参注射液联合紫杉醇与顺铂治疗晚期卵巢癌的临床疗效[J].实用肿瘤杂志,2015,30(5):465-468.
[42]王媛.复方苦参注射液配合腹腔灌注化疗治疗卵巢癌腹腔积液临床研究[J].中国中医药信息杂志,2015,22(5):25-28.
[43]张涛,徐海亭,惠华,等.洛铂与复方苦参注射液联合腹腔灌注治疗卵巢癌并发恶性腹水的疗效及其对肿瘤坏死因子的影响[J].中国基层医药,2017,24(15):2281-2284.
[44]郝玉珍,吴英,冀秋凤,等.消癌平联合PC方案治疗晚期卵巢癌的临床研究[J].西北国防医学杂志,2016,37(10):679-681.
[45]李凤霞,宋爱英,唐寅,等.消癌平注射液直肠给药联合常规化疗治疗上皮性卵巢癌的临床观察[J].中国药房,2015,26(20):2815-2817.
[46]汤巍巍,于明新,尉阳,等.新辅助化疗联合鸦胆子油注射剂治疗晚期卵巢癌的疗效观察[J].中医药导报,2014,20(4):21-22.
[47]徐卫东.鸦胆子油乳联合化疗治疗复发性卵巢癌37例[J].浙江中西医结合杂志,2008,18(6):382-383.
[48]王淳,董秀,王梅,等.消癌平注射液增敏奥沙利铂抑制卵巢癌Caov-3细胞的增殖[J].肿瘤防治研究,2012,39(7):780-783.
[49]白晓菊.中药注射剂抗肿瘤品种分析[J].中药药理与临床,2009,25(3):72-73.
[50]赵楠,李玉花,吴效科.鸦胆子油乳及联合顺铂对卵巢癌SKOV3裸鼠移植瘤生长抑制的影响[J].中国中西医结合杂志,2015,35(1):57-62.
[51]李戈,赵晨,思金华,等.19种中药注射剂联合TACE治疗中晚期肝细胞癌的网状Meta分析[J].兰州大学学报(医学版),2016,42(3):58-63,72.
[52]张涛,凌解春,秦裔丽.参麦注射液临床新用[J].时珍国医国药,2005,16(3):245.
[53]王宁军,芦殿荣,杨柳,等.华蟾素缓解癌性疼痛作用机制的研究进展[J].世界中西医结合杂志,2016,11(4):590-592.
[54]刘云霞,匡唐洪,蒋沈君.华蟾素注射液改善晚期癌症患者生活质量的临床观察[J].中国中医药科技,2005,12(1):45-46.
[55]贾小晴,孙萍,等.华蟾素抗肿瘤成分及作用机制研究进展[J].辽宁中医药大学学报,2017,19(3):215-217.
[56]赵洁敏,吴爱珍,石亮荣,等.参芪扶正注射液联合多西紫杉醇加氟脲嘧啶/亚叶酸钙治疗晚期胃癌的临床观察[J].中国中西医结合杂志,2007,27(8):736-738.
[57]耿维凤,陈敏.参芪扶正注射液临床初步观察[J].中国医院药学杂志,2003,23(9):554-555.
[58]李经才.药理学总论[M].北京:人民卫生出版社,2005:536.
[59]苏瑞,李玲,徐宏彬,等.复方苦参注射液对胃肠道恶性肿瘤辅助治疗的临床观察[J].中国医院药学杂志,2015,35(4):322-325.
[60]宣丽君.复方苦参注射液对化疗减毒作用的临床观察[J].实用中医内科杂志,2005,19(3):275.